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Purpose: We propose a nosology for inborn errors of metabolism
that builds on their recent redefinition.
Methods:We established a strict definition of criteria to develop a
self-consistent schema for inclusion of a disorder into the nosology.
Results: We identified 1015 well-characterized inborn errors of
metabolism described in the literature. In addition, there are 111
less well-characterized conditions that may be inborn errors but do
not meet strict criteria for inclusion in the current nosology.
Conclusion: We provide a master list of all currently recognized
inborn errors of metabolism grouped according to their pathophy-
siological basis, with the hope of setting a standard against which
new errors should be defined, as well as to promote awareness and
foster collaboration in the area. With the rapid advances in the field
of genetics in recent years, it is likely that this nosology will need to
be updated in the near future, a process that will benefit from
broader input and collaboration of experts in the field to improve
future versions of the proposed classification.
Genetics in Medicine (2019) 21:102–106; https://doi.org/10.1038/
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INTRODUCTION
The first inborn error of metabolism (IEM) was described in
1902 by Sir Archibald Garrod.1 Since then, many more have
been described, variously estimated as >600 (ref. 2) or >700
(ref. 3). However, the exact number of IEMs first begs the
question: what is an IEM? This subject has recently been
addressed elsewhere.4 In the era of clinical genomics, IEMs
can no longer be considered as only monogenic conditions
involved in the synthesis or catabolism of molecules within a
specific pathway, leading to measurable abnormalities in
classic biochemical laboratory methods. Rather, it has been
suggested that an IEM should instead be defined to include
any condition in which the impairment of a biochemical
pathway is intrinsic to the pathophysiology of the disease.
A nosology is a classification of diseases. Nosologies for
other groups of disorders have grappled with issues of
definition. For example, a nosology of skeletal dysplasias was
first introduced almost 50 years ago,5 it has been regularly
updated ever since, and most recently is in its ninth iteration.6
Similarly, the first classification of primary immunodeficien-
cies was also proposed in the 1970s7 after the World Health
Organization sponsored a Primary Immunodeficiency Expert
Committee to classify human primary immune defects. Once
established, a nosology provides a framework for diagnosing,
studying, and treating a group of disorders. A formal attempt
to systematically establish a nosology of IEMs, as well as to
continuously curate its content to maintain its relevance, has
never been proposed. The purpose of the present article is to
develop such a nosology, and to apply it to the recently
established Inborn Errors of Metabolism Knowledgebase
(IEMbase).8
MATERIALS AND METHODS
We first established specific criteria to classify a disorder as an
IEM. These criteria are summarized in Table 1, and explained
in detail here.
In the current nosology, we ascribe to the recent
redefinition of an IEM as any condition that leads to a
disruption of a metabolic pathway, irrespective of whether it is
associated with abnormalities in biochemical laboratory tests.
We not only include primary enzyme or transporter
deficiencies or superactivities, but also chaperone deficien-
cies—such as DNAJC12 deficiency presenting with hyper-
phenylalaninemia—or deficiencies in transcription factors
that can induce metabolic abnormalities, such as HCF1
deficiency with methylmalonic aciduria, GATA1 deficiency
with excess uroporphyrin I excretion, or NRF2 superactivity
with hypohomocysteinemia.
We define single entries for individual enzyme deficiencies
regardless of severity. For example, we do not include three
Submitted 29 January 2018; revised 29 January 2018; accepted: 20 March 2018
Published online: 8 June 2018
1National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA; 2Division of Genetics and Metabolism, Children’s National Health System,
Washington, DC, USA; 3Departments of Pediatrics and Clinical Genetics, Academic Medical Centre, Amsterdam, The Netherlands; 4Department of Pediatrics, Centre for Molecular
Medicine and Therapeutics, University of British Columbia, Vancouver, BC, Canada; 5Department of Pediatrics, University of Pittsburgh School of Medicine, Department of
Human Genetics, Graduate School of Public Health, Pittsburgh, Pennsylvania, USA; 6Dietmar-Hopp Metabolic Center, University Children’s Hospital, Heidelberg, Germany.
Correspondence: Carlos R. Ferreira (carlos.ferreira@nih.gov)
ARTICLE © American College of Medical Genetics and Genomics
102 Volume 21 | Number 1 | January 2019 | GENETICS in MEDICINE
separate entries for Gaucher disease types 1, 2, and 3, as this
classification is largely dependent on severity of the enzyme
deficiency, and not on a different pathophysiology. Similarly,
there is only one entry for lysosomal acid lipase deficiency,
and not two separate entries for Wolman disease and
cholesteryl ester storage disease. However, we provide the
alternative nomenclature for these disorders in a separate
column. On the other hand, single enzyme deficiencies are
included as two separate entries when they lead to clearly
delineated phenotypes, not strictly associated with severity.
For example, GM1 gangliosidosis and Morquio syndrome
type B are both caused by β-galactosidase deficiency, but the
phenotype is clearly distinct. Similarly, a deficiency of acid
ceramidase can lead to Farber disease (of variable severity),
but also to a different phenotype of spinal muscular atrophy
with progressive myoclonic epilepsy, with no known correla-
tion between the degree of enzyme activity and the
phenotypic presentation. In the case of ATP7A-related distal
motor neuropathy, the clinical and metabolic findings are
completely unrelated to those of Menkes disease or occipital
horn syndrome, and in fact the neuropathy phenotype is
caused by distinct variants leading to a distinct pathomechan-
ism. Such situations generate separate entries for defects in
the same protein.
Conditions that can have both autosomal recessive and
autosomal dominant inheritance are included under the same
entry as long as they share a similar mechanism of disease, as
is the case with MCT1 deficiency, SCOT deficiency,
5-oxoprolinase deficiency, ISCU deficiency, or hereditary
hyperekplexia type 1. However, in some disorders, the
different pattern of inheritance is associated with a completely
different phenotype; for example, biallelic variants in genes
encoding the subunits of succinate dehydrogenase lead to a
leukodystrophy, while heterozygous variants in the same
genes lead to familial paragangliomas, the latter likely via
inhibition of HIF prolyl hydroxylases.9 For some disorders,
the line is somewhat blurry. For example, autosomal
dominant GTP cyclohydrolase deficiency manifests as dopa-
responsive dystonia without hyperphenylalaninemia, while
the autosomal recessive form manifests with earlier onset of
severe neurologic dysfunction and hyperphenylalaninemia
due to a more severe and systemic tetrahydrobiopterin
deficiency. Thus, the current separation of this enzymatic
defect into two separate entries is maintained, based on
different clinical and biochemical findings, and different
management. However, intermediate phenotypes do exist, as
patients have been described with biallelic variants in GCH1
but only exhibiting dopa-responsive extrapyramidal symp-
toms without hyperphenylalaninemia,10,11 while some hetero-
zygous carriers exhibit hyperphenylalaninemia when given a
phenylalanine load but otherwise are asymptomatic.12 Simi-
larly, autosomal dominant hypermethioninemia caused by
dominant negative variants in MAT1A is given a separate
entry from the autosomal recessive MAT I/III deficiency
caused by loss-of-function variants. In the case of Δ-1-
pyrroline-5-carboxylate synthase deficiency, a predominant
spastic paraplegia phenotype can be seen both with autosomal
dominant or recessive inheritance, while a phenotype that
includes neurologic involvement and cutis laxa can also be
inherited in either an autosomal dominant or recessive
fashion. The dominant inheritance of either the cutis laxa
phenotype or the spastic paraplegia phenotype is likely due to
dominant negative variants.13,14 In such cases, we include two
entries for the same enzyme deficiency based on the clinical
phenotype (as opposed to four separate entries, based on both
phenotype and inheritance pattern). Classifying X-linked
disorders as dominant or recessive can be problematic given
the fact that females can have manifestations from X-linked
conditions classically defined as recessive.15,16 Nevertheless,
we elected to include two separate entries for X-linked
disorders that present with different phenotypes in hetero-
zygote females as compared with hemizygote males. Examples
of this include the X-linked recessive CK syndrome or
X-linked dominant CHILD syndrome, both caused by
variants in NSDHL, or the X-linked recessive MEND
syndrome versus X-linked dominant chondrodysplasia punc-
tata, both caused by variants in EBP.
Different variants in some proteins can lead to either
deficiency or superactivity, with drastically different pheno-
types. Examples include the monocarboxylate transporter 1,
δ-aminolevulinic acid synthase, phosphoribosylpyropho-
sphate synthetase, and glucokinase. Additionally, different
variants in the same protein can lead to disparate mechanisms
of disease. For example loss-of-function variants in the FTL
Table 1 Criteria used for inclusion of an inborn error of metabolism in the current nosology
The disruption of a metabolic pathway is considered necessary and sufficient for inclusion
Regardless of laboratory abnormalities in standard biochemical tests
Regardless of association with clinical manifestations of disease (unless the defect is universal to all humans)
Severity alone is not considered sufficient for separation into different entries when a single gene product is involved
A different pathomechanism is considered necessary for separation into different entries when a single gene product is involved, regardless of the mode
of inheritance
The involvement of different gene products is considered sufficient for separation into different entries, even if the phenotype is similar
The error must have been reported in more than a single family, and the involvement of the gene product must have been well characterized on an
enzymatic or molecular level
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gene lead to hereditary L-ferritin deficiency, while gain-of-
function variants in exon 4 that alter the reading frame
disrupt protein folding and stability and lead to neuroferri-
tinopathy. Additionally, variants in the 5’ noncoding iron-
responsive element (IRE) of the gene lead to
hyperferritinemia-cataract syndrome. Such cases are included
as separate entries based on the discrepant pathophysiology.
Another criterion used in the current nosology was to
include entries based on the particular gene product involved,
and not solely on the clinical phenotype. For example, we
included separate entries for glycine encephalopathy caused
by the deficiency of glycine decarboxylase or aminomethyl-
transferase. Similarly, defects in many different mitochondrial
transfer RNAs can lead to the MELAS phenotype, while
defects in multiple nuclear-encoded mitochondrial proteins as
well as mitochondrial DNA genes can lead to Leigh
syndrome. We include separate entries for involvement of
each such gene product.
Numerous biochemical phenotypes that do not cause
clinical disease have been described. Pentosuria, one of the
first IEMs described by Archibald Garrod during his
Croonian lectures, is asymptomatic.17 Other IEMs classically
considered “nondiseases” include histidinemia, hydroxyproli-
nemia, or cystathioninuria. In contrast, some biochemical
phenotypes originally thought to be clinically significant have
been called into question (short-chain acyl-CoA dehydrogen-
ase and 3-methylcrotonyl-CoA carboxylase deficiencies).
Finally, some IEMs originally considered not to be clinically
relevant have subsequently been associated with a disease
phenotype, such as pterin-4-α-carbinolamine dehydratase
deficiency.18,19 All of these conditions have been included in
the current nosology, as the term inborn error of metabolism
does not by necessity denote a disease. We have not included
variants in metabolism that are ubiquitous in humans as
compared with other species, for example, lack of L-
gulonolactone oxidase or urate oxidase activities.
Whenever possible, entries are named according to the
protein involved, unless it is impractical. For example, the
name “iminoglycinuria” is well established, and to insist
instead on the protein-based name “proton amino acid
transporter deficiency with or without imino acid transporter
deficiency” is not likely to be generally accepted. Similarly, the
name Hartnup disorder is well established, and preferable to
“B0 neutral amino acid transporter 1 deficiency.”
It should be noted that many entities could be assigned to
more than one group based on function and phenotype, a
situation that is acknowledged when pertinent. For example,
succinate dehydrogenase functions both in the Krebs cycle
and as part of the mitochondrial respiratory chain. In such
cases, the specific phenotype is included in the group most
directly related to the disease mechanism. For example,
fructose-1,6-bisphosphatase deficiency is included in the
group of disorders of gluconeogenesis, while it is only cross-
referenced in the group of disorders of fructose metabolism.
We have not included conditions that remain unpublished,
are not verified, or unlikely to have a genetic etiology. These
conditions are considered to be poorly characterized either
because their molecular basis has not been elucidated, because
only a few patients have been described in decades-old
reports, or because only individual families have been
reported. However, it is possible that these proposed IEMs
will be validated in the future.
Finally, certain contiguous gene deletions that include genes
encoding for enzymes often have a phenotype distinct from
the isolated (single gene) defect. Some examples include the
combined deletion of MAOA and MAOB,20–22 contiguous
ABCD1/DXS1375E deletion syndrome (also known as
CADDS),23 hypotonia–cystinuria syndrome,24,25 or complex
glycerol kinase deficiency. They are not included in the
nosology.
RESULTS
The complete list of IEMs according to our criteria is detailed
in Table S1. We define 1015 IEMs in 130 groups. An
additional 111 IEMs fall into the final category with lack of
substantiation (Table S2). Obviously, the total number of
IEMs will vary depending on the inclusion criteria. The most
prominent category was that of mitochondrial disorders
(groups 54–81) with 232 IEMs (22.9% of the total). Other
important categories included errors of metabolism of
nitrogen-containing compounds (groups 1–24) with 188
IEMs (18.5%), disorders of glycosylation (groups 115–130)
with 123 IEMs (12.1%), disorders of vitamin metabolism
(groups 25–38) with 79 IEMs (7.8%), storage disorders
(groups 100–108) with 67 IEMs (6.6%), disorders of sterol
and steroid metabolism (groups 95–97) with 46 IEMs (4.5%),
peroxisomal disorders (groups 109–113) with 27 IEMs (2.7%),
and disorders of metal metabolism (groups 40–43) with 25
IEMs (2.5%).
DISCUSSION
Different standard textbooks use different classifications of
IEMs,26–28 and 610 IEMs are currently tabulated in the
IEMbase.8 It should be noted that our current nosology was
not created with the intention of representing a new coding
system. However, the two most commonly used coding
systems, the International Classification of Diseases (ICD)
and the Systematized Nomenclature of Medicine–Clinical
Terminology (SNOMED-CT) are known to have wide gaps in
their inclusion of metabolic disorders, which could be filled by
the establishment of a formal nosology. In fact, a proposed
new coding system created by Dutch clinical specialists found
that there were no matches for 76% of metabolic disorders in
ICD-10, and 54% of metabolic disorders in SNOMED-CT.29
OMIM, although comprehensive and authoritative as an
online resource for genetic disorders–including inborn errors
of metabolism–also does not function as a formal nosology,
but rather as a catalog.30 On the other hand, there has been a
prior attempt to categorize a limited number of metabolic
disorders according to their clinical presentation, in order to
facilitate diagnosis.31 These aforementioned systems did not
formally attempt to classify metabolic disorders according to
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their pathophysiological and molecular basis, phenotype, and
inheritance.
A special mention should be given to the hierarchical
classification established by the Society for the Study of
Inborn Errors of Metabolism (SSIEM), accessible via their
website (http://www.ssiem.org/resources/IEC.asp) and last
updated in 2012. Subsequently, this classification appeared
in print in 2014 (ref. 32), and it includes 487 IEMs in 86
disease groups. This classification also grouped IEMs accord-
ing to their specific biochemical pathways and pathophysiol-
ogy, and went on to become the basis for sections 5C30 to
5C44 of ICD-11, scheduled to appear in 2018. Unfortunately,
this classification has not been updated in years and it
includes about half the number of IEMs included in our
nosology. In fact, a review of IEMs in the beta draft version of
ICD-11 (https://icd.who.int/dev11/l-m/en) reveals a great
number of missing IEMs. Our nosology does not only differ
from this prior classification in the fact that it's up to date, but
also in a number of other features. In particular, we tried to
categorize IEMs not only based on the involved pathway and
pathomechanism, but also based on the disease phenotype,
and on the specific protein or gene product that is deficient,
superactive, or dysregulated, all according to carefully
delineated inclusion criteria. Another difference is that we
decided not to include 111 less well-characterized IEMs, until
further confirmation of their validity as unique errors is
established based either on enzymatic or molecular grounds
for some IEMs, or reports of a second individual or family for
others. It is quite likely that many of these less well-
characterized IEMs will eventually be confirmed, and it is
possible that our decision to exclude them from the
established nosology could help raise awareness of the fact
that, for many of these conditions, further reports are needed
for confirmation of the phenotype.
The benefits of having a nosology for IEMs go beyond the
purely academic. First, it provides the medical community
with an overview of currently recognized IEMs grouped
according to their molecular etiology, with the intention that
this will set the standard against which potential new IEMs
should be defined. Second, it should also assist in identifying
patients with ultrarare disorders by providing practitioners a
complete list of potential diagnoses. For example, in a patient
with hypoglycemia in whom more common causes have been
excluded, a quick glance at the group of disorders of insulin
secretion can help to notice an ultrarare disorder such as
AKT2 superactivity (hypoinsulinemic hypoglycemia with
hemihypertrophy). Although not necessarily designed with
the intention of being a diagnostic tool, the nosology can act
as a quick reminder of the many differential diagnoses for a
given IEM, pointing in the appropriate direction for further
consultation of appropriate resources, and sets the stage for
the development of computer-based, machine learning
diagnostic algorithms. Finally, the grouping of conditions
can assist in selection of specific genes for sequencing panels
or targeted analysis of genome or exome data. Ultimately, we
hope that the nosology will promote awareness and foster
collaboration among individuals working in the area of
metabolism. One of the first applications of the current
nosology will be to restructure the IEMbase (www.iembase.
org), a knowledgebase of IEMs.
Of course a nosology is only as good as the uniform
application of its inclusion criteria, and we believe that the
proposed scheme is self-consistent, rather than contradictory.
However, any attempt of this type will by necessity be subject
to revision as a result of the rapid pace of progress in the field
of genetics. Thus, as new disorders are discovered, and our
understanding of the pathophysiology of existing disorders
continues to improve, frequent updates to the current
nosology will be critical to maintain its usefulness. We view
the current version as a stepping-stone for improved future
iterations, and will facilitate its continuous digital update via
the IEMbase.
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